Who is sponsoring NCT04508842?

NCT04508842 is sponsored by Hebei Yanda Ludaopei Hospital.

What drugs are being tested in NCT04508842?

Interventions in NCT04508842: CD19/CD22-Dual-STAR-T.

What condition does NCT04508842 study?

NCT04508842 studies Refractory and Relapsed B Cell Acute Leukemia.

Is NCT04508842 still recruiting?

NCT04508842 is currently terminated. Last updated 28 September 2022.

Last reviewed 2022-09-28 · How we verify

NCT04508842

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL)

Terminated Phase 1 Last updated 28 September 2022

What this trial tests

Phase 1 trial testing CD19/CD22-Dual-STAR-T in Refractory and Relapsed B Cell Acute Leukemia in 2 participants. Terminated before completion.

Timeline

10 October 2020

Primary endpoint
1 May 2022

1 May 2022

Quick facts

Lead sponsor	Hebei Yanda Ludaopei Hospital
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	10 October 2020
Primary completion	1 May 2022
Estimated completion	1 May 2022
Sites	1 location across China

Drugs / interventions tested

CD19/CD22-Dual-STAR-T — full drug profile →

Conditions studied

Refractory and Relapsed B Cell Acute Leukemia — all drugs for Refractory and Relapsed B Cell Acute Leukemia →

Sponsor

Hebei Yanda Ludaopei Hospital

Who can join

Adults 1 to 70, any sex, with Refractory and Relapsed B Cell Acute Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single center, single arm, open-lable phase I study to determine the safety and efficacy of CD19/CD22-Dual-STAR-T cells in patients with refractory and relapsed B cell acute leukemia .

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting CD22 for the Treatment of B-Cell Malignancies.
Shah NN, Sokol L. · · 2021 · cited 42× · PMID 34262884 · DOI 10.2147/itt.s288546
The TCR and LCK: foundations for T-cell activation and therapeutic innovation.
Woessner NM, Uleri V, Stepanek O, Minguet S. · · 2025 · PMID 41601693 · DOI 10.3389/fimmu.2025.1737013

Verify or expand the search:

Other Hebei Yanda Ludaopei Hospital trials

Trials by the same sponsor.

NCT05590091 — Study on Intelligent Nutrition Support Therapy for Hematopoietic Stem Cell Transplantation Recipients · NA · unknown
NCT05518357 — LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia · Phase 1 · completed
NCT04260945 — CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients · Phase 1 · completed
NCT04260932 — CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients · Phase 1 · completed
NCT04156217 — EBV-TCR-T Cells for EB Virus Infection After HSCT · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04508842 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hebei Yanda Ludaopei Hospital
Last refreshed: 28 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04508842.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing